St. Luke’s University Health Network (SLUHN) heart specialists are the first in the Lehigh Valley region to employ advanced ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

It is recommended that patients with mild aortic stenosis (i.e., AVA ≥1.5 cm 2; mean gradient ≤25 mm Hg with normal flow) may undergo repeat echocardiography after 9-12 months, while moderate ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Ord Minnett is approaching investors with another capital raising for Echo IQ, a $200 million market-capped stock focused on ...

The diagnosis of aortic stenosis is often made initially on physical examination and confirmed by echocardiography. The ECG findings of left ventricular hypertrophy with strain and left atrial ...

It isn’t always easy to hear the difference between aortic valve calcification and aortic stenosis, but an echocardiogram gives a very accurate measurement of the aortic valve opening. If you have ...

If not done already, your doctor will order an echocardiogram to confirm the diagnosis of aortic stenosis. The test uses ...

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...